VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2022 | Using TALEN gene editing to improve the efficacy of T-cell therapies

In this video, Roman Galetto, PhD, Cellectis, Paris, France, shares some insights into how TALEN gene editing can be used for different knockouts to minimize the risk of graft-versus-host disease (GvHD), as well as improve the overall efficacy and applicability of T-cell therapies used in the treatment of myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Transcript (edited for clarity)

TALEN gene editing has been done for different knockouts. We can knock out the gene we want in any case. So in our platform, we use always a knockout of the TCR alpha gene in order to disrupt TCR alpha beta complex from the cell surface and in that case, we will minimize the GvHD risk when we will be infusing those cells that comes from healthy donors in the patient. But we can use gene editing also to improve the efficacy of those cells or the applicability of those cells because we are able for example, we can do a CD52 knockout in the cells that will allow us to prolong a lymphodepletion period by using a reagent, an antibody like alemtuzumab will target CD52 and that it would normally kill any T-cell...

TALEN gene editing has been done for different knockouts. We can knock out the gene we want in any case. So in our platform, we use always a knockout of the TCR alpha gene in order to disrupt TCR alpha beta complex from the cell surface and in that case, we will minimize the GvHD risk when we will be infusing those cells that comes from healthy donors in the patient. But we can use gene editing also to improve the efficacy of those cells or the applicability of those cells because we are able for example, we can do a CD52 knockout in the cells that will allow us to prolong a lymphodepletion period by using a reagent, an antibody like alemtuzumab will target CD52 and that it would normally kill any T-cell. But having the knockout, we are able to have cells that have a prolonged persistence in the body.

Read more...

Disclosures

Cellectis employee

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter